Amid the Russia-Ukraine struggle, Pfizer Inc. on Monday stated it might now not get started new scientific trials in Russia and that it might donate “each and every greenback of benefit” from its subsidiary within the nation to Ukraine reduction reasons.
In a commentary, the corporate stated it stands with the “unified international group around the public, personal and civil society sectors towards the Russian struggle in Ukraine and the brutal state of affairs it has created”. Then again, the drugmaker stated that it’ll proceed to provide medications to the Russians.
Pfizer Inc. stated those choices align with their “patient-first values” and “make sure that each and every greenback of benefit derived from Russia will enhance Ukraine and its other people as they proceed to valiantly shield their country and freedom from this unprovoked and unjustified assault”.
Read full statement here:
Pfizer Inc. stands with the unified global community across the public, private and civil society sectors in opposition to the Russian war in Ukraine and the brutal situation it has created.
The international community has implemented unprecedented sanctions to Russia. As with all previous instances, for humanitarian reasons, medicines were excluded from these sanctions. Pfizer concluded that a voluntary pause in the flow of our medicines to Russia would be in direct violation of our foundational principle of putting patients first. Ending delivery of medicines, including cancer or cardiovascular therapies, would cause significant patient suffering and potential loss of life, particularly among children and elderly people.
However, maintaining the supply of medicines to Russia does not mean we will continue doing business as usual in Russia. Today we are announcing that effective immediately Pfizer will donate all profits of our Russian subsidiary to causes that provide direct humanitarian support to the people of Ukraine. This will be in addition to all other recently announced donations from Pfizer to Ukraine
Additionally, we will no longer initiate new clinical trials in Russia, and we will stop recruiting new patients in our ongoing clinical trials in the country. Pfizer will work with FDA and other regulators to transition all ongoing clinical trials to alternative sites outside Russia. Consistent with our commitment to putting patients first, we will continue providing needed medicines to the patients already enrolled in clinical trials.
Finally, while Pfizer doesn’t own or operate any manufacturing sites in Russia, we will cease all planned investments with local suppliers intended to build manufacturing capacity in the country.
These decisions align with our patient-first values and ensure that every dollar of profit derived from Russia will strengthen Ukraine and its people as they continue to valiantly defend their nation and freedom from this unprovoked and unjustified attack.
(To receive our E-paper on whatsapp daily, please click here. We allow sharing of the paper’s PDF on WhatsApp and different social media platforms.)
Printed on: Monday, March 14, 2022, 09:12 PM IST